Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 5/20 | 0.46 |
| ▸ | HTR2A | P28223 | 5/20 | 0.46 |
| ▸ | DRD3 | P35462 | 5/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7990792 | 1.00 | USP30 (0.48) | USP30MAPK14DRD2HTR2ADRD3 | |
| Bromide SCHEMBL5945892 | 1.00 | USP30 (0.48) | USP30MAPK14DRD2HTR2ADRD3 | |
| Bromide SCHEMBL7990796 | 1.00 | USP30 (0.48) | USP30MAPK14DRD2HTR2ADRD3 | |
| SCHEMBL29358671 | 0.99 | USP30 (0.49) | USP30MAPK14DRD2HTR2ADRD3 | |
| SCHEMBL3828127 | 0.99 | USP30 (0.49) | USP30MAPK14DRD2HTR2ADRD3 | |
| SCHEMBL5106853 | 0.99 | USP30 (0.49) | USP30MAPK14DRD2HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL7786685 | 0.98 | USP30 (0.48) | USP30MAPK14DRD2HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL7244869 | 0.98 | USP30 (0.48) | USP30MAPK14DRD2HTR2ADRD3 | |
| SCHEMBL7240506 | 0.98 | USP30 (0.48) | USP30MAPK14DRD2HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL7786681 | 0.98 | USP30 (0.48) | USP30MAPK14DRD2HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060034911-A1 | New oral immediated release dosage form | ASTRAZENECA AB (SE) | 2006-02-16 | — | — | US | claimed |
| US-6706710-B2 | SEROTONIN H5-HT1B- RECEPTOR ANTAGONIST, FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS DEPRESSION, ANXIETY, ETC. | ASTRAZENECA AB (SE) | 2004-03-16 | — | — | US | claimed |
| US-6291458-B1 | Morpholinobenzamide salts | ASTRAZENECA AB (SE) | 2001-09-18 | — | — | US | claimed |
| US-20060034911-A1 | New oral immediated release dosage form | ASTRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
| EP-1572158-A1 | A NEW ORAL IMMEDIATED RELEASE DOSAGE FORM | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004110447-A1 | USE OF TETRAHYDRONAPHTALENE DERIVATIVES FOR TREATMENT OF GI DISORDERS | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004052342-A1 | A NEW ORAL IMMEDIATED RELEASE DOSAGE FORM | ASTRAZENECA AB (SE) | 2004-06-24 | — | — | WO | disclosed |
| US-6706710-B2 | SEROTONIN H5-HT1B- RECEPTOR ANTAGONIST, FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS DEPRESSION, ANXIETY, ETC. | ASTRAZENECA AB (SE) | 2004-03-16 | — | — | US | disclosed |
| EP-1305303-A1 | NOVEL FORM OF (R)- i N /i - 5-METHYL-8-(4-METHYLPIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-2-NAPHTHYL]-4-MORPHOLINOBENZAMIDE | AstraZeneca AB (SE) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002008212-A1 | NOVEL FORM OF (R)-N-[5-METHYL-8-(4-METHYLPIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-2-NAPHTHYL]-4-MORPHOLINOBENZAMIDE | ASTRAZENECA AB (SE) | 2002-01-31 | — | — | WO | disclosed |
| EP-1149083-A1 | MORPHOLINOBENZAMIDE SALTS | AstraZeneca AB (SE) | 2001-10-31 | — | — | EP | disclosed |
| US-6291458-B1 | Morpholinobenzamide salts | ASTRAZENECA AB (SE) | 2001-09-18 | — | — | US | disclosed |
| WO-2000043378-A1 | NEW MORPHOLINOBENZAMIDE SALTS | ASTRAZENECA AB (SE) | 2000-07-27 | — | — | WO | disclosed |